Predicted to enable identical protein binding activity and ubiquitin protein ligase binding activity. Predicted to be involved in dopamine metabolic process; regulation of inclusion body assembly; and regulation of neurotransmitter secretion. Predicted to be located in cytoplasmic ribonucleoprotein granule and nucleoplasm. Orthologous to human SNCAIP (synuclein alpha interacting protein); PARTICIPATES IN Parkinson's disease pathway; INTERACTS WITH 2,2',4,4'-Tetrabromodiphenyl ether; 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil.
[Estradiol co-treated with TGFB1 protein] results in increased expression of SNCAIP mRNA and [Progesterone co-treated with Estradiol] results in decreased expression of SNCAIP mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCAIP mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCAIP mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCAIP mRNA
SNCAIP protein inhibits the reaction [Rotenone results in increased activity of CASP3 protein] and SNCAIP protein inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]
[NOG protein co-treated with Thimerosal co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SNCAIP mRNA